title: [Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma].
abstract: Several clinical studies have demonstrated the efficacy of subcutaneous immunotherapy with Il-2 alone in metastatic renal cell carcinoma (RCC). In an attempt to better define the clinical parameters which may predict the efficacy of treatment, the present study shows the results obtained with subcutaneous Il-2 alone in 91 evaluable metastatic RCC patients. IL-2 was injected subcutaneously at 3 million IU twice/day for 5 days/week for 6 weeks, corresponding to one immunotherapeutic cycle. In nonprogressing patients, a second cycle was given after 28-day rest period. A complete response (CR) was achieved in 2/91 patients. Moreover, 19/91 patients had a partial response (PR). Therefore, objective response (OR) rate was 21/91 (23%) patients. Stable disease (SD) was achieved in 41 patients, while the remaining 29 patients had a progressive disease (PD). OR rate was significantly higher in patients with a long disease-free survival than in patients with synchronous metastases, in nephrectomized patients than in the non-nephrectomized ones, and in patients with high than in those with low PS. The survival obtained in patients with CR or PA was significantly longer with respect to that found in patients with SD or PD. The toxicity was substantially low in all patients. This study confirms that the subcutaneous immunotherapy with IL-2 alone is an effective and well tolerated therapy of metastatic RCC.
authors.affiliation: Divisione di Radioterapia Oncologica, Ospedale S. Gerardo, Monza.
authors.forename: P
authors.initials: P
authors.lastname: Lissoni
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: G
authors.initials: G
authors.lastname: Tancini
authors.forename: M
authors.initials: M
authors.lastname: Cazzaniga
authors.forename: F
authors.initials: F
authors.lastname: Frigerio
authors.forename: M
authors.initials: M
authors.lastname: Chilelli
authors.forename: E
authors.initials: E
authors.lastname: Scardino
authors.forename: M
authors.initials: M
authors.lastname: Andres
authors.forename: P
authors.initials: P
authors.lastname: Favini
authors.forename: T
authors.initials: T
authors.lastname: Meroni
authors.forename: F
authors.initials: F
authors.lastname: Verwei
authors.forename: A
authors.initials: A
authors.lastname: Baccalin
authors.forename: M
authors.initials: M
authors.lastname: Sala
authors.forename: B
authors.initials: B
authors.lastname: Frea
authors.forename: E
authors.initials: E
authors.lastname: Kocjancic
authors.forename: F
authors.initials: F
authors.lastname: Rocco
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D007376:Interleukin-2